George Medicines’ triple combo potential to transform management of hypertension

UK-based George Medicines has announced the presentation of results from its two pivotal Phase III trials at a Hot Line session of the European Society of Cardiology (ESC) Annual Meeting in London.

The trials tested GMRx2, George Medicines’ novel, multi-mechanism triple combination candidate for the treatment of hypertension (high blood pressure [BP]), including initiation of treatment. GMRx2 contains best-in-class medicines, telmisartan, amlodipine and indapamide, in proprietary, triple quarter-dose (ultra-low dose), triple half-dose (low-dose) and triple standard-dose options, said George Medicines, an independent spin-out company from The George Institute for Global Health.

In the first Phase III trial, primary efficacy outcome was the difference between GMRx2 and its comparators in home-measured BP change from randomization to week 12. The trial met all primary safety and efficacy endpoints.